



## Genomic Insights and Translational Opportunities for Human Cancers

Guest Editors:

**Dr. Apostolos Zaravinos**

Cancer Genetics, Genomics and  
Systems Biology Laboratory,  
Basic and Translational Cancer  
Research Center (BTCRC),  
Nicosia 1516, Cyprus

**Dr. Ilias Georgakopoulos-  
Soares**

Department of Biochemistry and  
Molecular Biology, Penn State  
College of Medicine, Hershey, PA  
17033-0850, USA

Deadline for manuscript  
submissions:

**31 October 2024**

### Message from the Guest Editors

The field of cancer genomics has undergone a revolution in recent years with the advent of next-generation sequencing technologies and the development of new algorithms that can analyze large amounts of genomic information. These advances have enabled researchers to sequence cancer genomes with unprecedented accuracy, leading to new insights into the genetic basis of cancer, and opening up new avenues for cancer diagnosis, treatment, and prevention. By understanding the specific genetic mutations and transcriptomic changes that are present in a particular cancer, scientists can also develop more targeted and effective therapies. This Special Issue on genomic insights into human cancer focuses on the latest advances in cancer genomics, with an emphasis on the translational potential of these findings. The articles in this Special Issue will cover recent advances in cancer genomics, including: i) advances in bioinformatics algorithms, such as machine learning and artificial intelligence, and their application in cancer research; ii) novel cancer biomarkers, particularly those pertaining to liquid biopsies; and iii) other translational research relating to cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)